L

PriceLyell Immunopharma

LYEL

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Historical stock price chart and annual return over the past years

-97%

4 years

% Total

LYEL
-59%

4 years

Annual Return

LYEL